Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 473804, 10 pages
Review Article

Potential Therapeutic Use of PPAR -Programed Human Monocyte-Derived Dendritic Cells in Cancer Vaccination Therapy

1Department of Biochemistry and Molecular Biology, Medical and Health Science Center, University of Debrecen, 4010 Debrecen, Egyetem ter 1, Life Science Building, 4010 Debrecen, Hungary
2Apoptosis and Genomics Research Group of the Hungarian Academy of Sciences, Research Center for Molecular Medicine, Medical and Health Science Center, University of Debrecen, 4010 Debrecen, Hungary

Received 15 July 2008; Accepted 22 September 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Adrienn Gyöngyösi and László Nagy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Dendritic cells (DCs) can regulate all elements of the immune system, and therefore are an ideal target for vaccination. During the last two decades, as a result of extensive research, DCs became the primary target of antitumor vaccination as well. A critical issue of antitumor vaccination is the phenotype of the dendritic cell used. It has been recently shown that several nuclear hormone receptors, and amongst them the lipid-activated nuclear receptor and peroxisome proliferator-activated receptor gamma (PPAR ), have important roles in effecting the immunophenotype of human dendritic cells. It regulates primarily lipid metabolism and via this it influences the immunophenotype of DCs by altering lipid antigen uptake, presentation, and also other immune functions. In this review, we summarize the principles of antitumor vaccination strategies and present our hypothesis on how PPAR -regulated processes might be involved and could be exploited in the design of vaccination strategies.